• Calix Bio-Ventures Inc., of Vancouver, British Columbia, signed an agreement with Canaccord Genuit Corp. for placement of 6 million units of stock units at $0.25 per unit, for gross proceeds of $1.5 million to close May 30. Each unit is comprised of one common share and one-half of a common share purchase warrant, exercisable for 24 months at $0.40. Genaccord also will have the option to solicit additional units to raise up to $500,000 exercisable 48 hours before closing. Calix will also carry out a non-brokered private placement of up to $500,000 in units with similar terms. Funds will be used in part to finance the company's interest in Agrisoma. A previous private placement of 10 million common shares at $0.35 per share, announced March 9 has been canceled.

• Medicis Pharmaceutical Corp., of Scottsdale, Ariz., said it will offer $400 million in convertible senior notes due 2017, granting an option to underwriters for up to $50 million in additional convertible notes to cover overallotments. The notes will pay interest and will be convertible to cash, shares of class A common stock or a combination of cash and common stock. The notes will be mature on June 1, 2017.

• Savient Pharmaceuticals Inc., of East Brunswick, N.J., completed financing and debt restructuring of its 4.75 percent convertible senior notes due 2018 to raise approximately $44 million in net proceeds, and extended the maturity date of approximately 50 percent of the notes by about 15 months. It accomplished that by exchanging existing notes worth $108 million for units of senior secured discount notes and warrants. Note holders simultaneously purchased additional units resulting in net proceeds of $44 million.